| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Rapport Therapeutics, Inc.
13D/A
RAPP · 75383L102
|
4.2% |
9/18/2025
Event 9/11/2025
|
||||
| Sofinnova Venture Partners XI, L.P. ("SVP XI") | 4.0% | |||||
| Sofinnova Management XI, L.P. ("SM XI LP") | 4.0% | |||||
| Sofinnova Management XI, L.L.C. ("SM XI LLC") | 4.0% | |||||
| Dr. James I. Healy ("Healy") | 4.2% | |||||
| Dr. Maha Katabi ("Katabi") | 4.0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.